Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial

Kyverna Therapeutics, Inc.

KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.
KYSA-8 registrational trial of miv-cel in stiff person syndrome achieved positive primary analysis results.
Conference call held April 22, 2026 to review both data sets; slides furnished as Exhibit 99.1.
Data presented at AAN 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.